Primary PCI in Diabetic Patients: Clinical Outcomes and Challenges
DOI:
https://doi.org/10.70749/ijbr.v2i02.223Keywords:
Percutaneous Coronary Intervention, Diabetes, MACE, TIMI Flow, PakistanAbstract
Objective: To evaluate clinical outcomes and procedural challenges in diabetic patients undergoing primary Percutaneous Coronary Intervention (PCI) for ST-segment elevation myocardial infarction (STEMI) at the Department of Cardiology, Hayatabad Medical Complex, Peshawar.
Methodology: Conducted as an observational, single-center study from July 2022 to June 2023, 300 patients were enrolled, with equal numbers of diabetic and non-diabetic patients. Baseline demographics, clinical outcomes, and procedural success were analysed. Statistical tests included chi-square for categorical variables (major adverse cardiac events (MACE), stent thrombosis, restenosis, TIMI flow) and t-tests for age comparison. A significance level of p < 0.05 was set.
Results: Diabetic patients had a mean age of 60.9 years compared to 59.9 years in non-diabetic patients (t = -0.41, p = 0.685). The distribution of MACE was similar between groups (χ² = 1.31, p = 0.727), as were rates of stent thrombosis (χ² = 0.00, p = 1.000) and restenosis (χ² = 0.85, p = 0.355). TIMI flow rates also showed no significant difference by diabetic status (χ² = 3.32, p = 0.190), indicating comparable outcomes between diabetic and non-diabetic patients.
Conclusion: The study found no significant differences in primary PCI outcomes between diabetic and non-diabetic patients, suggesting that standardized procedural protocols may mitigate the heightened risk profile of diabetic patients. Multicenter studies with advanced diagnostic tools are recommended to enhance generalizability and optimize outcomes further in this population.
References
Chichareon P, Modolo R, Kogame N, Takahashi K, Chang C-C, Tomaniak M, et al. association of diabetes with outcomes in patients undergoing contemporary percutaneous coronary intervention: pre-specified subgroup analysis from the randomized global leaders study. Atherosclerosis 2020;295:45–53. https://doi.org/10.1016/j.atherosclerosis.2020.01.002.
Lee CH, Choi S-W, Jun S-W, Hwang J, Kim I-C, Cho Y-K, et al. clinical impact of diabetes mellitus on 2-year clinical outcomes following pci with second-generation drug-eluting stents; landmark analysis findings from patient registry: pooled analysis of the korean multicenter drug-eluting stent registry. PLoS One 2020;15:e0234362. https://doi.org/10.1371/journal.pone.0234362.
Dziewierz A, Zdzierak B, Malinowski KP, Siudak Z, Zasada W, Tokarek T, et al. diabetes mellitus is still a strong predictor of periprocedural outcomes of primary percutaneous coronary interventions in patients presenting with st-segment elevation myocardial infarction (from the orpki polish national registry). J Clin Med 2022;11:6284. https://doi.org/10.3390/jcm11216284.
Wang H, Song Y, Tang X, Xu J, Jiang P, Jiang L, et al. impact of unknown diabetes and prediabetes on clinical outcomes in “nondiabetic” chinese patients after a primary coronary intervention. Nutr Metab Cardiovasc Dis 2020;30:644–51. https://doi.org/10.1016/j.numecd.2019.11.013.
Claassens DMF, Vos GJA, Bergmeijer TO, Hermanides RS, van ’t Hof AWJ, van der Harst P, et al. a genotype-guided strategy for oral p2y 12 inhibitors in primary pci. N Engl J Med 2019;381:1621–31. https://doi.org/10.1056/NEJMoa1907096.
Mansoor B, . O, Iqbal M, Ali A, Malik F, Buzdar AW, et al. efficacy of primary percutaneous coronary intervention (pci) performed through a transradial approach in patients with st- segment elevation myocardial infarction (stemi) at a tertiary care cardiac center. Pakistan J Med Heal Sci 2023;17:498–502. https://doi.org/10.53350/pjmhs2023174498.
Rubartelli P, Bruzzone M, Ariel Sanchez F, Bologna E, Iannone A, Fedele M, et al. effect of pre-existing chronic kidney disease, anaemia and diabetes mellitus on mid-term mortality in patients with stemi treated with primary pci. Eur Heart J 2020;41. https://doi.org/10.1093/ehjci/ehaa946.1775.
Roffi M. regional differences in pci practice and clinical outcomes among patients with diabetes mellitus enrolled in a contemporary world-wide registry. Eur Heart J 2020;41. https://doi.org/10.1093/ehjci/ehaa946.3071.
Ahmed A, Varghese KS, Fusco PJ, Mathew DM, Mathew SM, Ahmed S, et al. coronary revascularization in patients with diabetes: a meta-analysis of randomized controlled trials and propensity-matched studies. Innov Technol Tech Cardiothorac Vasc Surg 2023;18:29–40. https://doi.org/10.1177/15569845221143420.
Zhao X, Lan J, Yu X, Zhou J, Tan Y, Sheng Z, et al. primary percutaneous coronary intervention in patients with type 2 diabetes with late/very late stent thrombosis and de novo lesions: a single-center observational cohort study of clinical outcomes and influencing factors. Front Cardiovasc Med 2021;8. https://doi.org/10.3389/fcvm.2021.653467.
Chen W-W, Chen J-Y, Li C-I, Liu C-S, Lin W-Y, Lin C-H, et al. diabetes mellitus associated with an increased risk of percutaneous coronary intervention long-term adverse outcomes in taiwan: a nationwide population-based cohort study. J Diabetes Complications 2020;34:107689. https://doi.org/10.1016/j.jdiacomp.2020.107689.
Zibaeenezhad MJ, Sayadi M, Mohammadi SS, Khorshidi S, Hadiyan E, Rasouli N, et al. the impact of diabetes mellitus on clinical outcomes after percutaneous coronary intervention with different stent sizes. J Tehran Univ Hear Cent 2023. https://doi.org/10.18502/jthc.v17i4.11609.
Liang X-Y, Li Y, Qiao X, Zhang W-J, Wang Z-L. clinical outcomes of very short term dual antiplatelet therapy in patients with or without diabetes undergoing second-generation drug-eluting stents: a systematic review and meta-analysis of randomized clinical trials. Front Cardiovasc Med 2021;8. https://doi.org/10.3389/fcvm.2021.655718.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Indus Journal of Bioscience Research
This work is licensed under a Creative Commons Attribution 4.0 International License.
